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Ovarian neoplasms are rare tumours of steroid cell origin. These tumours present clinically due to the associated excess
production of either androgenic or oestrogenic gonadal steroid hormones. The clinical picture is dictated by the specific
hormone(s) produced and influenced by the age of the patient. The case is a 59-year-old woman who presented with a five-
year history suggestive of androgen excess. She underwent a hysterectomy and right-sided oophorectomy at age 28 years
for dysfunctional uterine bleeding. Virilisation was confirmed on clinical examination and the testosterone excess
biochemically localised to the ovaries. A left-sided oophorectomy was performed. The clinical picture and testosterone
excess persisted after surgery. Follow-up radiological investigations identified adnexal material that on resection proved to
be remnant ovarian tissue. Histopathology confirmed the presence of a steroid cell tumour within the remnant tissue. The
biochemical androgen excess resolved and the clinical features improved dramatically.
Case presentation
A 59-year-old Caucasian woman presented with complaints of
excessive hair growth, a deepening of the voice and temporal
balding. She had first noted the symptoms five years previously,
with an initial concern of new onset facial hair growth. The hir-
sutism was progressive, followed by the onset of male-pattern
baldness and subsequent deepening of the voice. The voice
changes prompted endocrine consultation. There was no
other significant prior medical history apart from well-controlled
asthma that never required oral corticosteroids. She denied use
of any pharmacotherapy (topical and oral) or any over-the-
counter supplements. Her weight remained unchanged over
the course of the five years. Her menarche was at age 13 years
with a regular menstrual cycle reported during adolescence.
She conceived spontaneously and had two live children. At
age 28 years, she underwent a total abdominal hysterectomy
(TAH) and right salpingo-oophorectomy for dysfunctional
uterine bleeding, which rendered her amenorrhoeic. She experi-
enced symptoms compatible with perimenopause at 51 years
and recalls hot flushes and vaginal dryness around the time
that subsided spontaneously.
Physical examination revealed a hirsute woman, normotensive
with a body mass index (BMI) of 30 kg/m2 (weight: 77 kg;
height: 1.60 m) indicating obesity class I with central accentua-
tion. No other clinical features of insulin resistance were
present. Terminal hair growth involved the chin, upper lip,
face, breasts, thighs, back and abdomen. Severe hirsutism
was confirmed with a modified Ferriman–Gallwey score of≥
15. She had no acne or abnormal skin pigmentation. Features
of virilisation in the form of severe hirsutism, profound male-
pattern baldness and clitoromegaly (1.5 × 2.5 centimetres)
were present. Abdominal examination revealed no palpable
masses. The rest of the systemic examination was unremark-
able with no features suggestive of cortisol or mineralocorti-
coid excess.
Baseline biochemical results are tabulated in Table 1. Biochemi-
cal testing documented elevated serum luteinising hormone
(LH) and follicle stimulating hormone (FSH) levels along with
low circulating oestradiol in keeping with the patient’s postme-
nopausal state. The serum total testosterone was markedly high
at 10.8 nmol/l (normal female range: 0.5–2.6 nmol/l). The weaker
androgens, dehydroepiandrosterone sulphate (DHEAS) and
androstenedione, respectively predominantly from adrenal
and ovarian origin, were both within the normal laboratory refer-
ence ranges. A random, unstimulated 17α- hydroxyprogester-
one (17OHP) level was slightly elevated at 4.3 nmol/l (female
reference range 0.6–2.2). Pathological cortisol excess was
excluded based on an 8:00 am serum cortisol level that sup-
pressed following administration of low dose (1 mg) exogenous
dexamethasone to less than 50 nmol/l (32 nmol/l).
The clinical and baseline biochemical assessment confirmed
excess androgen production and an ovarian origin was con-
sidered to be most likely. The differential diagnosis included
ovarian hyperthecosis, a virilising ovarian tumour, and also
late-onset congenital adrenal hyperplasia (CAH). Last-mentioned
aetiology was thought unlikely to result in virilisation and was
excluded with the documentation of an unstimulated 17α-
OHP level below 5.1 nmol/l, the level above which ACTH stimu-
lation is suggested.1
Pelvic ultrasound (US) was requested with due cognisance that a
virilising ovarian tumour may be too small to visualise. US con-
firmed an absent uterus, in keeping with the reported hyster-
ectomy. The right-sided ovary was not seen, as expected with
the history of prior surgical removal. The left ovary appeared
anatomically normal. Despite the normal ultrasonography, a
possible ovarian tumoral source of androgen was still con-
sidered and the patient was referred for a left salpingo-oophor-
ectomy, before further imaging was performed. Histopathology
demonstrated no tumour and the ovarian histology was
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reported as being within normal limits. A benign papillary cyst
adenofibroma in the Fallopian tube was deemed an incidental
finding.
No clinical improvement followed the surgical removal of the
left ovary. Biochemistry following the surgical intervention is
tabulated in Table 2. The virilisation worsened and was
accompanied by the documentation of persistently elevated
serum testosterone levels. Anti-androgenic therapy was initiated
and resulted in some clinical improvement with a less frequent
need to shave and a lowering of serum testosterone levels to
4.6 nmol/l. Upon discontinuation of anti-androgen therapy, the
testosterone level increased again to a value more than three
times the upper female normal range, i.e. to 8.3 nmol/l. The per-
sistently elevated serum testosterone level despite an apparent
complete surgical removal of the uterus, fallopian tubes and
both ovaries prompted further investigation to identify the per-
sistent source of testosterone. A repeat normal DHEAS
(2.8 nmol/,) and a normal ACTH-stimulated 17α-OHP again
excluded the likelihood of an adrenal source. A normal β-
human chorionic gonadotropin (HCG) of < 2 IU/L and a
normal α-fetoprotein level (8.0 ug/l) eliminated a rare androgen
secreting tumour associated with these tumour markers, such as
hepatoblastomas.
The pelvic US was repeated. A small (20 × 17 millimetre), solid
mass of uncertain significance, located posterior and cranial to
the right cervical stump, was noted. Peristalsis was absent, but
US-doppler demonstrated some arterial flow in the centre of
the mass. The cervix was visualised, the uterus was noted to
be absent and yet again neither ovary could be identified. A
pelvic magnetic resonance imaging (MRI) study was performed
to further delineate the right adnexal mass. The MRI reported
only varicosities in the parametrium bilaterally and no mass
lesions.
The patient underwent laparoscopic surgery almost two years
after initial presentation. Tissue in the right adnexa, macroscopi-
cally identified to be ovarian tissue, was noted in keeping with
the most recent pelvic US findings and was laparoscopically
resected. The remainder of the right infundibulopelvic ligament
was mobilised proximally and resected as well. No macroscopic
ovarian remnant was identified here. The cervical stump was
found to be embedded in an adhesive complex that involved
the urinary bladder and ureters. The anatomy in this area was
restored and the cervical stump excised. No other masses or
abnormalities were noted. One month after the laparoscopic
surgery, the clinical features of hyperandrogenism improved sig-
nificantly with biochemical resolution of the testosterone excess
(testosterone level 0.6 nmol/l).
On histopathology, the excised adnexal tissue was confirmed to
be ovarian in nature, with a 9 mm tumour identified adjacent to
the hilum. The tumour comprised polygonal cells with central
monomorphic nuclei and eosinophilic cytoplasm. Many cells
contained lipofuscin pigment. No Reinke’s crystalloids, nuclear
clustering or fibrinoid necrosis of vessel walls to suggest a
Leydig cell tumour were present. Immunohistochemical staining
was positive for both melan-A and inhibin. The diagnosis of a
steroid cell tumour not otherwise specified (NOS) was therefore
made (Figures 1–2). No ovarian tissue was present in the right
infundibulopelvic ligament or cervical stump.
Discussion
The case presented with new-onset hirsutism after menopause
and demonstrated ongoing hirsutism and virilisation despite
surgical removal of both ovaries. Ultrasound detected tissue of
uncertain significance in the right adnexa that was surgically
removed. Histopathology confirmed residual ovarian tissue
and identified a steroid cell tumour (NOS) within. This case illus-
trates the importance of evaluating new-onset hirsutism after
menopause and highlights the importance and utility of clinical
and biochemical surveillance after surgical resection of
hormone-producing lesions. The importance is demonstrated
in this case where persistent ovarian androgen production
occurred despite bilateral oophorectomies.
Hirsutism is defined as male-pattern terminal hair growth in
women. It is a common finding in certain ethnic groups and is
not necessarily pathological. Hirsutism is quantified by the Ferri-
man–Gallwey score in premenopausal women and a score of≥ 8
are consistent with a diagnosis of hirsutism. A score greater than
15 is regarded as severe hirsutism as evident in our case with a
calculated score of 16.2 The Ferriman–Gallwey score has been
criticised for its inability to take all androgenic skin areas into
account and for lacking validation in certain ethnic groups as
well as in postmenopausal women.3 The Ferriman–Gallwey
score, however, remains a valuable clinical tool as it provides
us with a quantitative, standardised assessment of the extent
of male-pattern hair growth. Hirsutism presenting after meno-
pause should always prompt a meticulous history aimed at dif-
ferentiating new-onset hirsutism from ongoing hirsutism.
Accompanying signs of virilisation are always pathological and







FSH 72.9 23–116.3 IU/l*
LH 41.8 15.9–54.0 IU/l*
Oestradiol 61.9 <18–505 pmol/l
Testosterone 10.8 0.5–2.6 nmol/l
DHEAS 1.8 0.5–5.6 μmol/l
Androstenedione 6.0 1.0–11.5 nmol/l
17αOH-progesterone 4.3 0.6–2.2 nmol/l
Cortisol post 1 mg DXM 32 < 50 nmol/l
*Postmenopausal reference interval.
Table 2: Biochemical assessment following left oophorectomy
Biochemical parameter Post-surgery On antiandrogen therapy No antiandrogen therapy Normal reference range
Testosterone 4.6 8.3 0.5–2.6 nmol/l
DHEAS 2.8 2.9 0.5–5.6 μmol/l
17α- OHP* 5.1 0.6–2.2 nmol/l
β-HCG < 2 < 10 IU/l
α fetoprotein 8.0 < 8 ug/l
*Post ACTH stimulation, value > 30.3 nmol/l confirms the diagnosis of congenital adrenal hyperplasia.
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concerning and necessitate further investigations to exclude or
confirm the presence of an androgen-secreting tumour.3
Our patient presented with new-onset hirsutism after meno-
pause. The hirsutism was accompanied by virilisation (voice dee-
pening, male-pattern balding and clitoromegaly) and an
investigation of the source of androgen production was appro-
priately undertaken.
Androgen-secreting tumours arise from the adrenal gland or
ovary. Biochemically, serum testosterone levels in excess of
4 mmol/l in females generally support the suspicion of a tumor-
ous aetiology.4,5 Virilising ovarian tumours are exceedingly
scarce and represent about 10% of ovarian neoplasms.4 The
term ‘virilising tumour of the ovary’ includes Leydig cell
tumour, Sertoli cell tumour, ovarian thecomas and steroid cell
tumour.4,6
A steroid cell tumour not otherwise specified (NOS) was
diagnosed in our case. These tumours originate from ovarian
tissue and from ectopic adrenal glands.4,6 Steroid cell
tumours account for less than 0.1% of ovarian neoplasms. The
subtype ovarian steroid cell tumour NOS is the most common
variant and represents approximately 60% of all steroid cell
tumours.6
Ovarian hyperthecosis, where testosterone production is attrib-
uted to persistent, functional theca cells, must also be
Figure 1: Haematoxylin and eosin stain demonstrating clusters of polygonal cells with granular eosinophilic cytoplasm with central nuclei
(40x magnification).
Figure 2: The immunohistochemical staining here demonstrates the universal positivity for inhibin, characteristic of steroid cell tumours.
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considered in the differential diagnosis of postmenopausal
females with new-onset hirsutism. The androgen production is
thought to be unmasked in the postmenopausal state through
the loss of granulosa cell mediated aromatisation of testoster-
one to oestradiol.7 This process is reinforced by increased
levels of LH and insulin that reduces hepatic sex-hormone
binding globulin (SHBG) production. Analogous to polycystic
ovarian syndrome (PCOS), the decreased SHBG leads to
increases in bioavailable, unbound testosterone with enhanced
androgenic effects.7 Mildly increased ovarian 17OHP levels,
similar to the level initially noted in our patient (4.3 nmol/l,
female reference range 0.6–2.2), can occur in PCOS and are
attributed to intrinsic theca cell overactivity.8
The differentiation between ovarian hyperthecosis and virilising
ovarian tumour is often challenging, with significant overlap
between the clinical picture and biochemical findings of these
conditions.7 It has been proposed that ovarian hyperthecosis,
unlike primary ovarian tumour, is gonadotrophin dependent,
with higher levels of FSH and LH seen in hyperthecosis com-
pared with corresponding levels in women with virilising
ovarian tumour. Absolute FSH cut-off values have been pro-
posed in the literature to support the diagnosis of virilising
ovarian tumour. An FSH value≤ 35 IU/l has a sensitivity of 90%
and specificity of 92%, whereas a cut-off FSH value of < 22.3
IU/l has a sensitivity and specificity of 77% and 87% to diagnose
virilising ovarian tumour.9 Our patient had a baseline FSH level
of 72.4 IU/l. She would therefore have been erroneously cate-
gorised as ovarian hyperthecosis based on these FSH cut-off cri-
teria. The bilateral oophorectomy and the absence of readily
demonstrable ovarian tissue on imaging, along with the fact
that the hirsutism onset occurred three years after the onset
of menopause, made a diagnosis of ovarian hyperthecosis
unlikely.
Steroid cell tumour NOS are usually benign and often too
small to be detected with radiological imaging, including
MRI.7,9 The fact that the pelvic US revealed the abnormality
in our patient highlights the fact that radiological investigation
remains operator dependent and underpins the importance of
skilled ultrasonographers in settings with limited access to
MRI. Steroid cell tumour NOS presents at any age, with 43
years the mean age at presentation.10,11 In the majority of
patients (75%), these tumours are functional and present
with a clinical picture of hormonal excess.11 The most
common presentation is with virilisation (56–77%) due to tes-
tosterone overproduction and as noted in our case. The clini-
cal presentation of androgen excess is modified by age and
masked in postmenopausal women who seldom seek
medical attention due to associated menstrual irregularities.
Oestradiol secretion occurs in 6–23% of patients with these
tumours and hyperoestrogenemia can result in irregular men-
struation or postmenopausal bleeding.11,12 Cushing’s syn-
drome, due to ectopic ACTH or CRH production, is described
in up to 10% of patients.11 Our patient did not develop any
overt clinical features of Cushing’s syndrome and cortisol
excess was also excluded biochemically.
Histopathology remains the gold standard for the diagnosis of
steroid cell tumours NOS. Characteristically these tumours are
benign, well circumscribed and non-calcified with a lobulated
appearance. The tumours are also typically solid with a yellow
or orange section surface because of intracytoplasmic lipids.
On microscopic examination, the tumour cells typically have a
nested arrangement but can be organised into columns or
cords resembling adrenal zona glomerulosa and zona fascicu-
lata. Cytologically, cells are polygonal or round with distinctive
cell borders, central nuclei and prominent nucleoli. The cyto-
plasm varies from eosinophilic to clear and vacuolated. The
absence of cytoplasmic Reinke’s crystals helps differentiate this
tumour from the Leydig cell neoplasm. Immunohistochemical
staining helps to distinguish steroid cell tumours from other
stromal cell tumours as shown in the index case (see Figures 1
and 2). Based on the limited data available, the recommended
management of steroid cell tumour NOS is primarily surgical.
Conclusion
This case emphasizes the importance of having a high index of
suspicion for an occult testosterone-secreting ovarian tumour in
a virilised postmenopausal woman without an obvious ovarian
mass on radiologic studies. Prompt surgical management can
lead to complete resolution of symptoms and normalisation of
testosterone levels as illustrated in our case.
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